Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUYNEI)

Drug Name
Amoxicillin Drug Info
Synonyms
AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Acute otitis media AB00 Approved [1]
Bacterial infection 1A00-1C4Z Approved [2]
Staphylococcus aureus infection Approved [1]
Streptococcal pneumonia Approved [1]
Urinary tract infection GC08 Approved [1]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [1]
Sinusitis CA0A.Z Investigative [1]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
33613
ChEBI ID
CHEBI:2676
CAS Number
CAS 26787-78-0
TTD Drug ID
DMUYNEI
VARIDT Drug ID
DR00190
INTEDE Drug ID
DR0104
ACDINA Drug ID
D00035

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial Cell membrane (Bact CM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teicoplanin DMAQ2LK Bacterial infection 1A00-1C4Z Approved [35]
Delamanid DMXE76K Multi-drug resistant tuberculosis MG52.00 Approved [36]
Diphtheria-tetanus vaccine DM0FSIM Clostridium infection 1A04 Approved [37]
D2A21 DMYJ2QB Burn and burn infection ND90-NE2Z Phase 3 [38]
DPK-060 DM059CZ Atopic dermatitis EA80 Phase 2 [39]
Brilacidin DMXI9BP Acute bacterial skin infection 1C41 Phase 2 [40]
LTX-109 DMXEQ0R Bacterial infection 1A00-1C4Z Phase 2 [41]
Friulimicin DMUI8F3 Bacterial infection 1A00-1C4Z Phase 1 [42]
IDR-1018 DM1RNT7 Bacterial infection 1A00-1C4Z Phase 1 [43]
Lotilibcin DMDLTCU Bacterial infection 1A00-1C4Z Phase 1 [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Folic Acid DMEMBJC Colorectal carcinoma Approved [47]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [46]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [46]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [48]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [46]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [49]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [50]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 1 (SLC15A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [52]
Ampicillin DMHWE7P Acute epiglottitis Approved [53]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [54]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [55]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [56]
Ceftriaxone DMCEW64 Acute gonococcal cervicitis Approved [57]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [52]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [54]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [54]
Valsartan DMREUQ6 Chronic heart failure BD1Z Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 2 (SLC15A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ampicillin DMHWE7P Acute epiglottitis Approved [58]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [59]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [60]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [61]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [58]
Valaciclovir DMHKS94 Genital herpes 1A94 Approved [62]
Cefaclor DMJXDGC Bacterial infection 1A00-1C4Z Approved [4]
Aminolevulinic acid hci DMS4BLQ Acne vulgaris ED80 Approved [63]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [64]
Cefixime DMY60I8 Acute gonococcal cervicitis Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporter 1 (SLC22A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [65]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [66]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [67]
Aciclovir DMYLOVR Genital herpes 1A94 Approved [67]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [67]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [68]
Olmesartan medoxomil DMWBHRY High blood pressure BA00 Approved [69]
Zalcitabine DMH7MUV Human immunodeficiency virus infection 1C62 Approved [70]
FLUORESCEIN DMQTFAO Ocular disease 1F00.1Z Approved [71]
Tenofovir DM1IS6U Chronic hepatitis B virus infection Approved [72]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [73]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [74]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [75]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [76]
Verapamil DMA7PEW Angina pectoris BA40 Approved [77]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [78]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [79]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [80]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [81]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [76]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Beta-lactamase (blaB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ticarcillin DM4ME02 Aspiration pneumonia Approved [19]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [17]
Ticarcillin DM4ME02 Aspiration pneumonia Approved [19]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [11]
Ticarcillin DM4ME02 Aspiration pneumonia Approved [19]
Ticarcillin DM4ME02 Aspiration pneumonia Approved [19]
Ticarcillin DM4ME02 Aspiration pneumonia Approved [19]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [20]
Ampicillin DMHWE7P Acute epiglottitis Approved [82]
Piperacillin DMTBKF3 Acute gonococcal cervicitis Approved [82]
Cefalotin DMVYSLE Bacteremia 1A73 Approved [82]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [82]
Cephaloridine DM4Y95F Gram-positive bacterial infection 1B74-1G40 Withdrawn from market [82]
Imipenem DMI9FBP Bacteremia 1A73 Approved [83]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [84]
Avibactam DM1AEH4 N. A. N. A. Approved [85] , [86]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [84] , [85]
Cefoxitin DMY8NC4 Acute gonococcal cervicitis Approved [84]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [14]
Meropenem DM62UHC Bacterial infection 1A00-1C4Z Approved [14]
Cefalotin DMVYSLE Bacteremia 1A73 Approved [87]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [11]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [21]
Cefoxitin DMY8NC4 Acute gonococcal cervicitis Approved [21]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [21]
Cefoxitin DMY8NC4 Acute gonococcal cervicitis Approved [21]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [21]
Cefoxitin DMY8NC4 Acute gonococcal cervicitis Approved [21]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [21] , [88]
Cefoxitin DMY8NC4 Acute gonococcal cervicitis Approved [21]
Cefotaxime DMEB837 Bacteremia 1A73 Approved [21]
Cefoxitin DMY8NC4 Acute gonococcal cervicitis Approved [21]
Ampicillin DMHWE7P Acute epiglottitis Approved [89]
Ticarcillin DM4ME02 Aspiration pneumonia Approved [18]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [11]
Ampicillin DMHWE7P Acute epiglottitis Approved [89]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [90]
⏷ Show the Full List of 37 Drug(s)
Drug(s) Metabolized By N-acylhomoserine lactone acylase (lacA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ampicillin DMHWE7P Acute epiglottitis Approved [13]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [13]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [13]
Carbenicillin DMLEDNK Infection of the upper and lower urinary tract GC08 Approved [13]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [13]
Drug(s) Metabolized By New delhi metallo-beta-lactamase NDM-1 (blaNDM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meropenem DM62UHC Bacterial infection 1A00-1C4Z Approved [9]
Drug(s) Affected By HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [91]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [34]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [92]
Allopurinol DMLPAOB Gout FA25 Approved [93]
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [94]
Selenium DM25CGV N. A. N. A. Approved [95]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [34]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [96]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [97]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class I histocompatibility antigen, B alpha chain (HLA-B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [98]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [99]
Allopurinol DMLPAOB Gout FA25 Approved [100]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [92]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [101]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [102]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [103]
Flucloxacillin DMNUWST Bacterial infection 1A00-1C4Z Approved [104]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [33]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [105]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By C-C chemokine receptor type 9 (CCR9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [30]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [106]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [107]
QUERCITRIN DM1DH96 Discovery agent N.A. Investigative [108]
Drug(s) Affected By C-C chemokine receptor type 4 (CCR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [30]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [109]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [110]
Arsenic DMTL2Y1 N. A. N. A. Approved [111]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [112]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [113]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [114]
KOJIC ACID DMP84CS Discovery agent N.A. Investigative [115]
Sulforaphane DMQY3L0 Skin disease EA00-EM0Z Investigative [116]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By HLA class I histocompatibility antigen, A alpha chain (HLA-A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [117]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [99]
Allopurinol DMLPAOB Gout FA25 Approved [118]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [93]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [33]
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [94]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [119]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [34]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [34]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By C-X-C chemokine receptor type 3 (CXCR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [30]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [101]
Arsenic DMTL2Y1 N. A. N. A. Approved [111]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [120]
MLN4924 DMP36KD Myelodysplastic syndrome 2A37 Phase 3 [121]
DNCB DMDTVYC Immune System disease 4A01-4B41 Phase 2 [122]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [123]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [113]
Formaldehyde DM7Q6M0 Discovery agent N.A. Investigative [124]
Nickel chloride DMI12Y8 Discovery agent N.A. Investigative [122]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aromatase (CYP19A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [125]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [126]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [127]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [128]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [127]
Methotrexate DM2TEOL Anterior urethra cancer Approved [129]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [130]
Bifonazole DM3KN7V Fungal infection 1F29-1F2F Approved [131]
Quercetin DM3NC4M Obesity 5B81 Approved [132]
Fluoxetine DM3PD2C Bipolar depression Approved [127]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 11B2, mitochondrial (CYP11B2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aldosterone DM9S2JW Hypertension BA00-BA04 Approved [133]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [130]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [29]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [101]
Potassium Chloride DMMTAJC Hypokalemia 5C77 Approved [134]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [135]
Mitotane DMU1GX0 Adrenocortical carcinoma 2D11.Z Approved [136]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [137]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [138]
Testosterone DM7HUNW Hot flushes GA30 Approved [133]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [139]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [140]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [139]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [140]
Sulfinpyrazone DMEV954 Gout FA25 Approved [141]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [139]
Zafirlukast DMHNQOG Asthma CA23 Approved [139]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [139]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [142]
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [143]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [144]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [145]
Quercetin DM3NC4M Obesity 5B81 Approved [146]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [147]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [148]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [28]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [149]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [150]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [151]
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [152]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [153]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [154]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [155]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [156]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [157]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [158]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [159]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [160]
Quercetin DM3NC4M Obesity 5B81 Approved [161]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [162]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sulfiredoxin-1 (SRXN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [155]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [163]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [164]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [165]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [28]
Ethacrynic acid DM60QMR Edema MG29 Approved [166]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [167]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [153]
Leflunomide DMR8ONJ Arthritis FA20 Approved [168]
Clodronate DM9Y6X7 Hypercalcaemia 5B91.0 Approved [153]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By C-X-C motif chemokine 10 (CXCL10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [169]
Quercetin DM3NC4M Obesity 5B81 Approved [170]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [171]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [119]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [172]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [28]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [173]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [174]
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [175]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [101]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-8 (CXCL8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [176]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [177]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [178]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [179]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [180]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [181]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [182]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [156]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [183]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [182]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Organic solute transporter subunit alpha (SLC51A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [163]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [145]
Methotrexate DM2TEOL Anterior urethra cancer Approved [184]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [185]
Quercetin DM3NC4M Obesity 5B81 Approved [146]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [186]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [119]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [187]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [185]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [188]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Cell membrane (Bact CM) TTXT4D5 NOUNIPROTAC Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [4]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [4]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [5]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Metallo-beta-lactamase (blaM) DEK9VG2 BLAN1_KLEPN Substrate [8]
Beta-lactamase (blaB) DEW193R BLA1_KLEPN Substrate [8]
New delhi metallo-beta-lactamase NDM-1 (blaNDM) DEBGCYQ A0A345N7K5_SALET Substrate [9]
Beta-lactamase (blaB) DE7IH52 AMPC_CITFR Substrate [10]
Metallo-beta-lactamase (blaM) DEPCQ12 Q68K11_ALCXX Substrate [8]
Beta-lactamase (blaB) DEV0KWQ Q8KT52_9BACT Substrate [10] , [11]
Beta-lactamase (blaB) DEACNTL Q2F4C6_SHISO Substrate [12]
N-acylhomoserine lactone acylase (lacA) DEIU0XN A0A0A1VBK6_9BURK Substrate [13]
Beta-lactamase (blaB) DET9I1W BLAC_BACUN Substrate [14]
Beta-lactamase (blaB) DENJ2SQ BLAB_BACFG Substrate [14]
Beta-lactamase (blaB) DED0TBR A0A414M273_9BACE Substrate [15]
Beta-lactamase (blaB) DEX8KJO A6NX15_9FIRM Substrate [16]
Beta-lactamase (blaB) DEAYSTX C0W968_9FIRM Substrate [17]
Beta-lactamase (blaB) DERGEVU C3WC84_FUSMR Substrate [18] , [19]
Beta-lactamase (blaB) DEQMISO F9Z530_ODOSD Substrate [18] , [19]
Beta-lactamase (blaB) DEHFJ4G Q8KT51_9BACT Substrate [18] , [19]
Beta-lactamase (blaB) DEHPJRC Q8KT60_9BACT Substrate [18] , [19]
Beta-lactamase (blaB) DEITMS0 Q9XBM2_ACIFE Substrate [20]
Beta-lactamase (blaB) DE5HV8P A0A4Q5I6I2_9BACE Substrate [14]
Beta-lactamase (blaB) DE47ARF B5WXV2_9BACT Substrate [21]
Beta-lactamase (blaB) DEG2PK9 B5WXV3_BACOV Substrate [14]
Beta-lactamase (blaB) DEWHJ7A B5WXV7_BACT4 Substrate [14]
Beta-lactamase (blaB) DEU1RXB BLAC_BACVU Substrate [14] , [22]
Beta-lactamase (blaB) DETDS7E A0A2S0LB67_9FLAO Substrate [10]
Beta-lactamase (blaB) DE37FJH C6JIU1_FUSVA Substrate [18]
Beta-lactamase (blaB) DEC7JEF A0A1S1G219_9NEIS Substrate [10]
Beta-lactamase (blaB) DEP7MN1 Q9X4S7_PREIN Substrate [23]
Beta-lactamase (blaB) DEAILCM A0A246EJV2_9BACT Substrate [23] , [10]
Beta-lactamase (blaB) DET4XFN Q8KT59_9BACT Substrate [10]
Beta-lactamase (blaB) DEE8742 O32372_CAPOC Substrate [24]
Beta-lactamase (blaB) DEY09SU C9MN73_9BACT Substrate [10]
Beta-lactamase (blaB) DEQLVCA C9LD75_9BACT Substrate [23]
Beta-lactamase (blaB) DE2IL34 C2M7J0_CAPGI Substrate [24]
Beta-lactamase (blaB) DE1NJIW B6VMJ3_PHOAA Substrate [25] , [26]
Beta-lactamase (blaB) DEDIMN9 A0A413GBG0_9BACE Substrate [14]
Beta-lactamase (blaB) DEJ8X2W A0A412YFL9_9BACE Substrate [14]
Beta-lactamase (blaB) DEFEVNH A0A381DV31_9FLAO Substrate [24]
Beta-lactamase (blaB) DEAPGXV A0A347B2J2_9BACT Substrate [10]
Beta-lactamase (blaB) DE0PDVC A0A2A3N1K0_CAPSP Substrate [24]
Beta-lactamase (blaB) DEQL32N A0A250F962_9FLAO Substrate [24]
Beta-lactamase (blaB) DE9HF0I A0A120A1C6_BACSE Substrate [14]
Beta-lactamase (blaB) DESHI6O A0A108T9G3_9BACE Substrate [14]
Beta-lactamase (blaB) DEZS3N4 A0A069QS91_PRELO Substrate [10]
Beta-lactamase (blaB) DE5NSUX A0A095XPV0_9FIRM Substrate [10]
Beta-lactamase (blaB) DEQ1CTE A0A2T4TNV5_9BACT Substrate [27]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Gene/Protein Processing [28]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [29]
C-C chemokine receptor type 4 (CCR4) OT68KZ9B CCR4_HUMAN Drug Response [30]
C-C chemokine receptor type 9 (CCR9) OT5FSOD8 CCR9_HUMAN Drug Response [30]
C-X-C chemokine receptor type 3 (CXCR3) OTIGS220 CXCR3_HUMAN Drug Response [30]
C-X-C motif chemokine 10 (CXCL10) OTTLQ6S0 CXL10_HUMAN Gene/Protein Processing [31]
Cytochrome P450 11B2, mitochondrial (CYP11B2) OTIOLWYN C11B2_HUMAN Gene/Protein Processing [29]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Gene/Protein Processing [32]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Drug Response [33]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Gene/Protein Processing [34]

References

1 Amoxicillin FDA Label
2 Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
5 The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
6 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
7 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
8 Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
9 Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
10 Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
11 Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
12 IncU plasmid harbouring bla CTX-M-8 in multidrug-resistant Shigella sonnei in Brazil. J Glob Antimicrob Resist. 2018 Sep;14:99-100.
13 A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
14 Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
15 Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res. 2013 Mar;57(3):523-35.
16 The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin. Br J Oral Maxillofac Surg. 1990 Jun;28(3):180-4.
17 ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300.
18 Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
19 Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
20 ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9.
21 Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
22 Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres. J Antimicrob Chemother. 1990 Sep;26(3):361-70.
23 Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
24 High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
25 Yersinia enterocolitica and Photorhabdus asymbiotica beta-lactamases BlaA are exported by the twin-arginine translocation pathway. Int J Med Microbiol. 2013 Jan;303(1):16-24.
26 Xenorhabdus luminescens (DNA hybridization group 5) from human clinical specimens. J Clin Microbiol. 1989 Jul;27(7):1594-600. Case Reports
27 High prevalence of cfxA beta-lactamase in aminopenicillin-resistant Prevotella strains isolated from periodontal pockets. Oral Microbiol Immunol. 2002 Apr;17(2):85-8.
28 Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
29 Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):142-53.
30 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
31 Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
32 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
33 HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013.
34 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
35 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
36 Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
37 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
38 In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
39 The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29.
40 Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
41 A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
42 Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
43 Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.
44 Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287.
45 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
46 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
47 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
48 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
49 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
50 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
51 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
52 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
53 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
54 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
55 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
56 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
57 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
58 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
59 Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
60 The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
61 Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
62 Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
63 PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
64 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
65 Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
66 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
67 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
68 Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
69 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
70 Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
71 Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
72 Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8.
73 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
74 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
75 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
76 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
77 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
78 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
79 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
80 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
81 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
82 Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
83 Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
84 Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572.
85 Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying blaKPC-2 reveals a heterogenous population and reversible genotype. mSphere. 2018 Sep 26;3(5). pii: e00408-18.
86 Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
87 Antibacterial activity of cefoperazone against anaerobic bacteria (author's transl). Jpn J Antibiot. 1980 Nov;33(11):1171-82.
88 Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against beta-lactam antibiotics. J Antimicrob Chemother. 2015 Mar;70(3):701-9.
89 Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
90 Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents. Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8.
91 The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. doi: 10.1111/j.1365-2222.2004.02197.x.
92 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
93 A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
94 Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.
95 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
96 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
97 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
98 Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008 Oct;9(10):1543-6. doi: 10.2217/14622416.9.10.1543.
99 Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010 Mar;11(3):349-56. doi: 10.2217/pgs.09.162.
100 HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9. doi: 10.1073/pnas.0409500102. Epub 2005 Mar 2.
101 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
102 HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013 Jul;54(7):1307-14. doi: 10.1111/epi.12217. Epub 2013 May 20.
103 Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002 Mar 30;359(9312):1121-2. doi: 10.1016/S0140-6736(02)08158-8.
104 HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.
105 Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol. 2011 Jul;109(1):42-6. doi: 10.1111/j.1742-7843.2011.00681.x. Epub 2011 Mar 16.
106 Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
107 Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
108 Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer. Arch Med Res. 2014 Aug;45(6):445-54.
109 Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
110 Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
111 Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
112 Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017 Dec;56(6):1077-1084. doi: 10.1002/mus.25733. Epub 2017 Aug 29.
113 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
114 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
115 Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.
116 Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One. 2014 Jan 22;9(1):e86787. doi: 10.1371/journal.pone.0086787. eCollection 2014.
117 HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011 Mar 24;364(12):1134-43. doi: 10.1056/NEJMoa1013297.
118 Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011 May;21(5):303-7. doi: 10.1097/FPC.0b013e32834282b8.
119 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
120 Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci. 2010 Aug;116(2):467-76. doi: 10.1093/toxsci/kfq138. Epub 2010 May 10.
121 The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-B activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014 Mar 15;20(6):1576-89. doi: 10.1158/1078-0432.CCR-13-0987.
122 Preliminary discovery of novel markers for human cell line activation test (h-CLAT). Toxicol In Vitro. 2021 Aug;74:105154. doi: 10.1016/j.tiv.2021.105154. Epub 2021 Mar 25.
123 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
124 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
125 Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
126 Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
127 Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
128 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
129 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
130 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
131 Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
132 Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
133 [Association study between a polymorphism of aldosterone synthetase gene and the pathogenesis of polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi. 2003 Feb;38(2):94-7.
134 Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008 Apr 28;584(2-3):424-34. doi: 10.1016/j.ejphar.2008.02.001. Epub 2008 Feb 12.
135 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
136 Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013 May 21;20(3):371-81.
137 Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol Scand Suppl. 2009;(189):14-21.
138 Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens. 2002 May;15(5):389-93. doi: 10.1016/s0895-7061(02)02256-2.
139 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
140 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
141 Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
142 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
143 Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
144 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
145 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
146 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
147 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
148 Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
149 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
150 Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
151 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
152 Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
153 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
154 Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
155 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
156 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
157 Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
158 Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
159 Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
160 P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
161 Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
162 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
163 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
164 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
165 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
166 Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
167 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
168 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
169 Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
170 Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011 Sep 1;255(2):138-49.
171 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
172 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am J Pathol. 2005 Jul;167(1):285-98. doi: 10.1016/S0002-9440(10)62973-2.
173 Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
174 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
175 Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012 Dec;64(12):3856-66. doi: 10.1002/art.37691.
176 Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
177 Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
178 Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
179 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
180 Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
181 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
182 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
183 Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
184 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
185 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
186 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
187 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
188 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.